Eli Lilly’s Copellor®(Ixekizumab) now available in India for patients with psoriasis and psoriatic arthritis
Eli Lilly, a global pharmaceutical company, has launched Copellor®(Ixekizumab) in India for the treatment of moderate-to-severe plaque psoriasis and psoriatic…